Arkolith/Insider Trading/SNSE/Form 4

Krebs Stephanie

Chief Business OfficerSensei Biotherapeutics, Inc. (SNSE) · full profile →Form 4 · filed Dec 23, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
1
0 non-derivative · 1 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 20, 2024Grant(A)120K—$0120K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-24-030070) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML